GlassScriptPhysician profile
Waseem Shami
NPI 1043523137
$16,862.72
in general payments reported to CMS, 2019-2025
43 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,727 · 2020: $1,438 · 2021: $1,868 · 2022: $1,902 · 2023: $3,523 · 2024: $3,752 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,063 · Travel and Lodging: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,062.87 |
| Travel and Lodging | $864.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,158.37 | 2019-2025 | Cardiomems, Jot Dx, Aveir |
| Inari Medical, INC. | $1,767.87 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $1,668.56 | 2021-2025 | Symplicity G3, Abre, Turbohawk |
| Boston Scientific Corporation | $1,026.25 | 2022-2025 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply |
| Janssen Pharmaceuticals, INC | $1,024.42 | 2019-2024 | Xarelto |
| Abiomed | $927.23 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $923.15 | 2019-2025 | |
| Pfizer INC. | $918.96 | 2020-2025 | |
| Amgen INC. | $878.51 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $568.03 | 2019-2024 | (Br5) Peripheral Ivus |
| Astrazeneca Pharmaceuticals LP | $523.27 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $470.30 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.89 | 2019-2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $424.92 | 2020-2022 | |
| Shockwave Medical, INC | $281.89 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $272.47 | 2019-2020 | |
| Cardiovascular Systems INC. | $272.33 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $260.43 | 2021-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.55 | 2019-2025 | Lifevest |
| Penumbra, INC. | $210.57 | 2023-2024 | Penumbra System |
| Merck Sharp & Dohme LLC | $195.36 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $170.90 | 2019 | |
| Medtronic Vascular, INC. | $153.52 | 2020 | |
| Surmodics, INC. | $145.91 | 2025 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, Pounce Thrombectomy |
| Lilly USA, LLC | $125.00 | 2023 | Mounjaro |
| Tactile Systems Technology INC | $102.57 | 2020-2024 | Flexitouch Plus, Entre Plus |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $87.99 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $80.73 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $69.29 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $68.98 | 2024-2025 | |
| Novo Nordisk INC | $64.04 | 2024-2025 | Wegovy, Ozempic |
| Kiniksa Pharmaceuticals, LTD. | $56.94 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $45.88 | 2019-2020 | |
| Astellas Pharma US INC | $40.08 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $39.73 | 2024 | Arcalyst |
| Angiodynamics, INC. | $33.81 | 2022 | |
| Chiesi USA, INC. | $27.72 | 2020-2023 | Kengreal |
| Impulse Dynamics (USA) INC. | $24.19 | 2023 | Optimizer |
| W. L. Gore & Associates, INC. | $15.69 | 2025 | Gore Viabahn Endoprosthesis |
| Cvrx, INC. | $15.25 | 2025 | Barostim Neo System |
| Cordis US Corp. | $15.02 | 2024 | Raiden3t |
| Genzyme Corporation | $12.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waseem Shami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.